Targeting the genetic and immunological drivers of cancer
|
|
- Harry Bradley
- 5 years ago
- Views:
Transcription
1 NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April
2 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1955, that involve significant risks and uncertainties. Forward looking statements can be identified by the use of forward looking words such as believes, expects, hopes, may, will, plan, intends, estimates, could, should, would, continue, seeks, pro forma, or anticipates, or other similar words (including their use in the negative), or by discussions of future matters such as the development of current or future product candidates, timing of potential development activities and milestones, business plans and strategies, possible changes in legislation and other statements that are not historical. Forward-looking statements are based on current expectations of management and on what management believes to be reasonable assumptions based on information currently available to them, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation potential delays in development timelines, negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks detailed in Mirati's recent filings on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission. Except as required by law, Mirati undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. 2 April 1, 2018
3 Mirati Therapeutics Answering Cancer s Challenges with a Targeted Approach We Are Experienced: A Team of Knowledgeable Oncology Drug Developers with a Track Record of Success in Rapidly Developing Multiple Therapies from Preclinical to the Market Oncology Experience Applying Proven Approaches to the Development of Sitravatinib and KRAS We Are Focused: Addressing Areas of Unmet Need for Patients in Large Patient Populations > Treating cancer progression after checkpoint inhibitor therapy > Targeting previously undruggable KRAS mutations across multiple tumor types Utilizing our Knowledge to Expedite Development of our Novel Approaches 3
4 Mirati s Development Programs Indication Preclinical Phase 1/1b Phase 2 Phase 3 Current Status NSCLC Phase 3 Expected to be Initiated 1H 2019 Immuno-oncology Sitravatinib + checkpoint inhibitor Bladder Phase 2 Initiated September 2018 Sitravatinib Oral Multi Kinase Inhibitor MOA Trials RCC, Head & Neck Mechanism of Action Trials Initiated September 2018 BeiGene Sitravatinib + Tislelizumab (anti-pd-1) NSCLC, RCC, HCC, Gastric, Ovarian, other BeiGene-led Trials Initiated November 2018 Targeted Single Agent CBL mutations NSCLC Melanoma Ongoing Phase 1b Focused on CBL in NSCLC and Melanoma KRAS Oral KRAS Inhibitors Targeted Single Agent MRTX849 G12C mutations Targeted Single Agent G12D mutations NSCLC CRC Pancreatic CRC, NSCLC, Pancreatic 1 st Patient Enrolled January Clinical Candidate Identification Underway 4 NSCLC = non-small cell lung cancer; CRC = colorectal cancer; RCC = renal cell cancer; HCC = hepatocellular cancer; IND = Investigational New Drug application; Tislelizumab (BeiGene s anti PD-1) MOA = Mechanism of Action
5 Immuno-Oncology Combinations Sitravatinib + Checkpoint Inhibitors 5 5
6 6 Sitravatinib in the Tumor Microenvironment May Restore Immune Response
7 Sitravatinib + Checkpoint Inhibitors Phase 2 Trial of Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC MRTX-500 Trial Phase 2 Trial Design Checkpoint Refractory NSCLC Expansion Criteria (PRs) Stage 1 Stage 2 Expansion Criteria (PRs) Stage 3 Key Inclusion Criteria: Advanced/metastatic NSCLC Documented radiographic progression on prior checkpoint inhibitor therapy Checkpoint Refractory NSCLC Documented Tumor Progression Prior Clinical Benefit No Prior Clinical Benefit 1 PR 3 PR n=9 n=8 n=40+ 1 PR 3 PR n=9 n=8 n=40+ Key Exclusion Criteria: No intervening therapy following progression on checkpoint inhibitor therapy No significant immune-related AEs with prior checkpoint therapy Exclude patients with known driver mutations Endpoints: Primary: ORR Secondary: Safety and tolerability, duration of response, PFS, OS, PK 7 Sitravatinib: Dose 120mg daily Nivolumab: Dose 3mg/kg every 2 weeks (full labeled dose) Study cycles of 28 days, with disease assessment scans every 2 cycles
8 Sitravatinib + Checkpoint Inhibitors Phase 2 Trial of Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC Maximum % Change from Baseline 70% 60% 50% 40% 30% 20% 10% 0% -10% -20% -30% -40% -50% -60% -70% -80% -90% -100% * On study as of 27-Aug-18 Complete response (1 target lymph node) BEST RESPONSE 1 (Evaluable Patients, N=56) Confirmed Response Stable Disease Progressive Disease 42/56 (75%) Clinical Benefit (SD+PR+CR) 18/56 (32%) Tumor Regression >30% * 11/56 (20%) Confirmed CR/PR 8 Study cycles of 28 days, with disease assessment scans every 2 cycles 1. Data cut-off: 27-Aug-2018; presented at ESMO 2018 Congress. Response data per investigator assessment, response confirmations updated after data cut-off.
9 Sitravatinib + Checkpoint Inhibitors Phase 2 Trial of Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC DURATION OF TREATMENT (Evaluable Patients, N=56) 50 * Confirmed Response Stable Disease Progressive Disease 40 Response first achieved 30 on study On study as of 27-Aug-18 Off study Complete response (1 target lymph node) 20 * Preliminary Kaplan-Meier Estimate of Median Duration of Response: 9.2 months Weeks Study cycles of 28 days, with disease assessment scans every 2 cycles 1. Data cut-off: 27-Aug-2018; presented at ESMO 2018 Congress. Response data per investigator assessment, response confirmations updated after data cut-off.
10 Clinical Practice in 1 st Line NSCLC has Changed The checkpoint refractory population is now in 2 nd line Sitravatinib + Checkpoint Inhibitors Prior Standard of Care No/Low PD-L1 High PD-L1 Stage IV Non-Squamous NSCLC Treatment Paradigm New Standard of Care No/Low PD-L1 High PD-L1 1L Platinum Doublet PD-1 1L PD-1 + Chemo PD-1 2L PD-(L)1 Platinum Doublet 2L Checkpoint Refractory Patients Platinum Doublet 3L Checkpoint Refractory Patients Docetaxel 3L 3 rd line population is diminishing Docetaxel By 2022 It is estimated that >50,000 patients in US/EU will be 2 nd line Checkpoint Refractory Kantar Health CancerMPact Treatment Architecture, Kantar Health projections. Excludes patients with addressable driver mutations
11 Sitravatinib + Checkpoint Inhibitors Phase 3 Randomized Trial in 2 nd Line NSCLC Two Opportunities for Approval in 2 nd Line NSCLC Interim Analysis: ORR, for Accelerated Approval Primary Analysis: OS, for Full Approval Preliminary Study Design Key Inclusion/Exclusion Criteria: Advanced, Non-Squamous NSCLC Checkpoint Refractory 2 nd Line NSCLC Documented Tumor Progression RANDOMIZATION 1:1 Sitravatinib + Nivolumab Docetaxel Primary Analysis OS N:~620 pts Progression on or following first line combination of PD-(L)1 inhibitor plus chemotherapy Excludes patients with known driver mutations Endpoints: Interim: ORR (for potential Subpart H accelerated approval) Primary: OS (for potential full approval) Secondary: PFS, duration of response, safety, tolerability Interim Analysis ORR Projected Phase 3 Timing: Study Initiation: 1H 2019 Interim ORR Analysis: Year End 2020 Primary OS Analysis: Year End
12 Sitravatinib + Checkpoint Inhibitors Docetaxel: An Efficacy Comparator Used in Prior 2 nd Line NSCLC Trials Advanced NSCLC 2 nd Line or Subsequent Therapy Trial Compound Pts ORR, % DOR, Mos PFS, Mos (Range) SD, % CBR, % (CR+PR+SD) OS, Mos (Range) 057 [1] Docetaxel n=290 12% ( ) 42% 54% 9.4 ( ) CheckMate Nivolumab n=292 19% ( ) 25% 44% 12.2 ( ) Checkpoint Naïve Patients Atezolizumab n=425 14% ( ) 35% 49% 13.8 ( ) Docetaxel n=425 13% ( ) 42% 55% 9.6 ( ) Not yet Pembrolizumab n=345 18% KEYNOTE reported 3.9 ( ) 10.4 ( ) 010 [3] Docetaxel n=343 9% ( ) 8.5 ( ) Checkpoint Refractory Patients MRTX-500 [4] Sitravatinib + Nivolumab n=56 20% 9.2* 6.8* 55% 75% 15.1* Borghaei H, et al. N Engl J Med. 2015;373: Rittmeyer A, et al. Lancet. 2017;389: Herbst RS, et al. Lancet. 2016;387: Mirati ESMO 2018 Congress Data presented is from separate studies and does not reflect results that might have been obtained from head-to-head studies. Results from Mirati's planned Phase 3 trial comparing sitravatinib + nivolumab to docetaxel may differ materially from prior studies presented. ORR = Overall Response Rate DOR = Duration of Response CBR = Clinical Benefit Rate (CR + PR + SD>14 weeks) * Preliminary Kaplan-Meier Estimate
13 Sitravatinib + Checkpoint Inhibitors Sitravatinib Value Creation and Expansion Strategy Mirati Development Activities 1 Advance Sitravatinib Towards Registration NSCLC Phase 3: 2 nd line checkpoint refractory Interim Analysis for Potential Accelerated Approval End of Extend Proof of Concept into Other Tumor Types Bladder Phase 2: checkpoint refractory Initial Proof of Concept Clinical Data Expected 2H Expand Mechanism of Action Data RCC Pre-surgical study HNSCC Pre-surgical study Early Mechanism of Action Data Expected 2H NSCLC = non-small cell lung cancer; RCC: renal cell cancer; HNSCC: head & neck squamous cell cancer Note: HNSCC pre-surgical mechanism of action study is investigator-sponsored
14 BeiGene / Mirati Collaboration: Expanding the Value of Sitravatinib Sitravatinib + Checkpoint Inhibitors BeiGene Development Activities 1 Generate Additional Proof of Concept Data in New Indications and With Another PD-1 Inhibitor BeiGene-Sponsored Clinical Trials 2 (in China and Australia) NSCLC: checkpoint naïve & refractory Independent confirmation in NSCLC with another PD-1 inhibitor RCC: checkpoint naïve & refractory Ovarian: checkpoint naïve HCC: checkpoint naïve & refractory Gastric: checkpoint naïve Initial Proof of Concept Clinical Data Expected 2H 2019 Initial Proof of Concept Clinical Data Expected 1H 2020 BeiGene will Fund and Conduct Multiple I/O Combination Trials with Sitravatinib 250+ Patients Across 5 Tumor Types in Initial Proof of Concept Trials Leverages BeiGene s Considerable Clinical Development Capabilities Access to Difficult-to-Enroll Patient Populations in China Provides Further Proof of Concept with Another PD-1 Inhibitor: Tislelizumab Sitravatinib is licensed to BeiGene, Ltd. in China, Asia (less Japan, Russia and India), Australia and New Zealand 2. In BeiGene s combination trials, Sitravatinib will be tested in combination with BeiGene s PD-1 inhibitor, tislelizumab NSCLC = non-small cell lung cancer; RCC: renal cell cancer; HNSCC: head & neck squamous cell cancer
15 Sitravatinib + Checkpoint Inhibitors Sitravatinib IO Combinations Summary Positive Interim Phase 2 Efficacy Data in Checkpoint Refractory NSCLC 1 (n=56) 42/56 (75%) demonstrated Clinical Benefit (Stable Disease, Partial Response or Complete Response) 11/56 (20%) achieved a confirmed Partial or Complete Response Preliminary Kaplan-Meier estimates Median Duration of Response: 9.2 months Median Progression Free Survival: 6.8 months Median Overall Survival: 15.1 months Registration Path: FDA Agrees to Phase 3 Design with Potential for Accelerated Approval Phase 3 randomized trial with potential for accelerated approval based on interim ORR analysis Phase 2 Clinical Trials in Expanded/Other Indications Checkpoint Refractory Bladder Cancer: Initial Phase 2 Proof of Concept data expected in 2H 2019 BeiGene-funded Phase 2 Trials: Initial Phase 2 proof of concept data expected in 2H 2019 / 1H Data presented at ESMO 2018 Congress; Data cut-off: 27-Aug-2018; Response data per investigator assessment, response confirmations updated after data cut-off.
16 Targeted Oncology Sitravatinib Single Agent: CBL Loss of Function Mutations 16 16
17 Single Agent Sitravatinib Sitravatinib: CBL Loss-of-Function Mutations in Cancer 17 Loss-of-function mutations in CBL result in increased target RTK activation in tumor cells that may act as oncogenic drivers
18 Single Agent Sitravatinib Phase 1b Trial of Single Agent Sitravatinib in Patients with CBL Mutations Summary of On-going Trial Initial Clinical Activity 1 in CBL Mutations is Encouraging 1/2 confirmed Partial Response in NSCLC 1/2 confirmed Partial Response in Melanoma (mucosal) (non-uv form which does not respond well to other treatments) Phase 1b Expansion Trial Design Patients with CBL Loss of Function Mutations Expansion Criteria (PRs) Stage 1 Stage 2 Expansion Criteria (PRs) Stage 3 Single Agent Sitravatinib Has Been Well Tolerated with Manageable Side Effects NSCLC Melanoma CBL Loss of Function Mutation (via NGS) n=8 2 PR 7 PR n=16 n=46 Single Agent Sitravatinib Program Focused on CBL in NSCLC and Melanoma Circulating tumor DNA assay (liquid biopsy) is now available to identify CBL loss of function mutations Clinical update expected in 2H 2019 to define single agent registration pathway Key Inclusion Criteria: Malignancy harboring loss of function CBL mutation Advanced metastatic or unresectable solid tumor malignancy Adequate bone marrow and organ function Key Exclusion Criteria: Symptomatic or uncontrolled brain metastases Endpoints: Safety, PK/PD Clinical Activity (ORR, DR, PFS, OS) Presented at ESMO 2018 Congress; data cut-off 4-Sep-2018
19 Targeted Oncology MRTX849: KRAS G12C Inhibitor 19 19
20 MRTX849 KRAS G12C Inhibitor KRAS: The Holy Grail of Mutated Oncogene Targets KRAS Signaling Drives Growth and Survival KRAS: The Most Frequently Mutated Gene in Human Cancer KRAS Mutations are Prevalent in High Mortality Cancers Pancreas Colorectal NSCLC 90% 44% 30% KRAS First Identified in 1980 s 1. Image from Genetics Home Reference Zehir A et al, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):
21 MRTX849 KRAS G12C Inhibitor Mutant KRAS is an Oncogenic Tumor Driver KRAS mutations occur early in tumor genesis and do not overlap with other tumor drivers Mutational Prevalence and Overlap in 1,357 Lung Adenocarcinomas 1 Mutant KRAS signaling is required for tumor cell survival Sensitivity of Cancer Cell Lines to shrna Knockdown of KRAS 2 HER2 (44) RET Fusion (20) KRAS G13 (37) EGFR L858R (109) BRAF (65) KRAS G12 (346) EGFR Exon 19 Deletion (102) KRAS Q61 (18) MET (47) ROS1 (29) ALK Fusion (42) Sensitivity Score Wild Type KRAS Cancer Cell Lines Mutant KRAS Zehir A et al, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6): McDonald et al, Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening, Cell 2017
22 KRAS G12C Mutations Occur Frequently in Multiple Tumor Types MRTX849 KRAS G12C Inhibitor KRAS G12C Mutation Frequency 1 G12C (14%) NSCLC adenocarcinoma Colorectal G12C (4%) Pancreatic G12C (2%) U.S Addressable Patients 2 : ~24, Mirati frequency estimates based upon the following sources and underlying databases: Zehir A et al, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6): ; Campbell et al, Nature Genetics 2016 Distinct patterns of somatic genome alterations in lung adenocarcinomas ; Bailey P et al, Nature 2016 Genomic analyses identify molecular subtypes of pancreatic cancer ; MSKCC Cancer Hot Spots database; NIH TCGA: The Cancer Genome Atlas 2. Mirati estimate based upon frequency data from sources above and epidemiology data from Globocan 2022 incidence projections (accessed January 2019) ; Total includes additional histologies
23 MRTX849 KRAS G12C Inhibitor KRAS G12C Mutations are Prevalent in a Large Population of Patients No Targeted Treatments Available for Patients with KRAS G12C+ Tumors 30,000 U.S. Patient Populations 2 KRAS G12C vs. ALK, RET and TRK Significant Commercial Opportunity 3-4x size of the ALK mutation population ($1.8B worldwide market in ) Diagnosed by Approved Assays Both tissue and liquid biopsy tests are commercially available Testing common in NSCLC and CRC U.S. Patient Population 25,000 20,000 15,000 10,000 5,000 0 KRAS G12C ALK RET TRK NSCLC CRC Other major-market sales (projected) for ALK inhibitors (Decision Resources NSCLC Forecast published Dec 2017) 2. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed January 2019) and frequencies by mutation; RET estimate does not include thyroid cancer
24 MRTX849 KRAS G12C Inhibitor Mirati s KRAS Program: Targeting KRAS G12C Mutations Targeting KRAS Historically Undruggable Shallow Binding Pocket GTP pocket 1. KRAS G12C has a cysteine present in its inactive form Switch II pocket KRAS G12C Can Be Inhibited Covalently 3. Inhibitor covalently binds to the cysteine and the induced Switch II pocket Cysteine KRAS Picomolar Affinity for GTP KRAS G12C 2. Binding to the cysteine opens an adjacent Switch II pocket KRAS G12C Inactive 4. KRAS G12C is irreversibly locked in the inactive state KRAS tumor cell death 24
25 MRTX849: A Potent and Selective Investigational KRAS G12C Inhibitor MRTX849 KRAS G12C Inhibitor Potent Selective Antiproliferation IC50s MRTX849, 3D format Cysteine Selectivity in H358 Cells MRTX849 (3 µm) IC50 (um) KRAS G12C cell lines Treated/Control Peptide Ratio 5,700 other cysteine peptides Ratio of significance Only modified cysteine is KRAS G12C Cervix Colon Pancreas Urinary Lung Peptide 25
26 MRTX849: Promising In Vivo Antitumor Activity Complete tumor regressions observed following oral administration in preclinical models MRTX849 KRAS G12C Inhibitor Tumor Volume(mm 3 ) MRTX849 Oral Administration CDX pancreatic model (MIA PaCa-2) Vehicle 1mg/kg 3mg/kg Vehicle 1 mg/kg Vehicle 1mg/kg 3mg/kg 10mg/kg 30mg/kg 100mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 100 mg/kg 10mg/kg Dose-Dependent Regressions Observed In Vivo Durable and complete responses seen at 30mg/kg and 100mg/kg doses Tumor response continued after cessation of treatment MRTX849 Tested in More than 20 In Vivo Models Tumor regressions observed in ~80% of all KRAS G12C in vivo models tested Similar activity seen in both cell-derived and patientderived tumor models S tart D osing End Dosing Day 30 & 100mg/kg* Preclinical Data Predicts Single Agent Activity Supports pursuit of an accelerated single agent development pathway based on response rate * Tumors did not recur despite cessation of treatment, indicating durable and complete responses 26
27 MRTX849 KRAS G12C Inhibitor Phase 1/2 Clinical Trial of MRTX849 in KRAS G12C+ Tumors Accelerated Dose Escalation Design Wide preclinical therapeutic index supports starting dose close to predicted active exposure Single patient cohorts 150mg starting dose with planned 100% escalations Intra-patient dose escalations Stage 1 Stage 2 Phase 1b Expansion Cohorts Opportunity to enroll additional patients based on early efficacy signals while still escalating to maximum tolerated dose (MTD) Advanced solid tumor types (lung, CRC and others) with G12C+ mutations only Single patient Cohorts 100% dose escalations until MTD reached Example: Pt 1 150mg Pt 2 300mg Pt 3 600mg Dose expansion when RP2D reached Registration-Enabling Protocol Design supports single arm registration from expansion cohorts without the need for a new protocol 27 ClinicalTrials.gov Identifier: NCT
28 MRTX849 KRAS G12C Inhibitor MRTX849: Summary Summary Potent: 1-20 nm potency in cellular assays Selective: 1,000 fold selective for KRAS G12C mutations over KRASwild type Orally Bioavailable: PK profile consistent with once daily oral dosing Highly Active in vivo: Complete durable regressions in KRAS G12C models Wide Therapeutic Index: Preclinical toxicology studies suggest a favorable safety profile Strong Patent Estate: First program patent issued in December 2018 Phase 1/2 Clinical Trial Open: Potential for initial efficacy data in 2H
29 Targeted Oncology KRAS G12D Program 29 29
30 KRAS G12D Discovery Program Mirati s Next KRAS Program: KRAS G12D KRAS G12D is a Driver Mutation Early oncogenic event Non-overlapping with other driver mutations, including KRAS G12C Large Patient Population Highly prevalent in pancreatic cancer (ductal adenocarcinomas) No targeted treatment options for patients with KRAS G12D+ tumors Leveraging Learnings from G12C Applying knowledge gained from designed targeting KRAS G12C Identified KRAS G12D leads G12D (35%) G12D (5%) KRAS G12D Mutation Frequency 1 Pancreatic Endometrial Colorectal NSCLC adenocarcinoma U.S Addressable Patients 2 : ~46,000 G12D (12%) G12D (5%) Sources: Zehir, Ahmet et al. Nature Med Mutational Landscape of Metastatic Cancer ; Krakstad et al. PLoS One 2012, High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers ; NIH TCGA: The Cancer Genome Atlas 2. Mirati estimate based upon frequency data from sources above and epidemiology data from Globocan 2022 incidence projections (accessed January 2019)
31 Mirati Therapeutics: Potential Value-Driving Catalysts in 2019 Sitravatinib Initiating Phase 3 Registrational Trial in NSCLC Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC Phase 3 Trial Initiation 1H 2019 Extending Proof of Concept into Additional Tumor Types Sitravatinib + Nivolumab in Checkpoint Refractory Bladder Phase 2 Initial Proof of Concept Data Sitravatinib + Tislelizumab in NSCLC, RCC, Ovarian Phase 2 Initial Proof of Concept Data (BeiGene) 2H H 2019 Expanding Clinical Mechanism of Action Data Sitravatinib + Nivolumab in Pre-Surgical RCC, HNSCC Initial Mechanism of Action Data 2H 2019 MRTX849 KRAS G12C Generating Clinical Data with Potential Best-in-Class KRAS G12C Inhibitor MRTX849 in KRAS G12C+ Tumors Phase 1/2 Early Proof of Concept Data 2H 2019 KRAS G12D Program Expanding KRAS Franchise into KRAS G12D KRAS G12D Program Lead Candidate Identification Q
32 Company Financials NASDAQ MRTX Cash (Q4 18)* $222.8M Shares Outstanding** 46.4M * Reported cash and investments as of December 31, Does not include $107.9 million of net proceeds from January 2019 offering ** As of February 22, 2019, includes 35.3 million shares of common stock and pre-funded warrants to purchase a total of 11.1 million shares of common stock. The pre-funded warrants have a per share 32 exercise price of $0.001.
33 NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation March
Targeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation January 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationA targeted oncology company developing a pipeline of cancer therapies for select patient populations.
A targeted oncology company developing a pipeline of cancer therapies for select patient populations. JEFFERIES GLOBAL HEALTHCARE CONFERENCE CHARLES BAUM, M.D., PH.D., PRESIDENT AND CEO JUNE 2015 Safe
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationExpertly targeting drivers of cancer in select patient populations. June 2016
Expertly targeting drivers of cancer in select patient populations v June 2016 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationCorporate Presentation. November 2017
v Corporate Presentation November 2017 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, contain
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationA targeted oncology company developing a pipeline of cancer therapies for precisely defined patient populations.
A targeted oncology company developing a pipeline of cancer therapies for precisely defined patient populations. Jefferies 2014 Global Healthcare Conference JUNE 2014 Safe Harbor Statement Certain statements
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationEvolution of Early Phase Trials: Clinical Trial Design in the Modern Era
Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Shivaani Kummar, MD, FACP Professor of Medicine (Oncology) Director, Phase I Clinical Research Program Co-Director, Translational
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationB I ABOUT BI DISEASE AREA & MECHANISM OF ACTION. For journalists outside UK/US/Canada only B A C K G R O U N D E R
For journalists outside UK/US/Canada only B I 1 4 8 2 6 9 4 1. About BI 1482694 2. Disease area & mechanism of action 3. Development status 4. Data overview 1. ABOUT BI 1482694 BI 1482694* (HM61713**)
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationJefferies 2015 Global Healthcare Conference June 1, 2015
Jefferies 2015 Global Healthcare Conference June 1, 2015 Page 0 Acceleron Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements are neither historical
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationCorporate Presentation. Curis, Inc All Rights Reserved
Corporate Presentation Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company ) within
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More information